Stevanato Group S.p.A.: Stevanato Group Reports Second Quart

- Raises Fiscal 2022 Guidance - Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and

Related Keywords

United States , United Kingdom , Belarus , China , Italy , Indiana , Zhangjiagang , Sichuan , Russia , Ukraine , Italian , America , Franco Moro , Franco Stevanato , Development Expenses , Exchange Commission On , Company Investor Relations , Solutions Segment , European Union , Stevanato Group , Diagnostic Solutions , Engineering Segments , Diagnostics Segment , Chief Executive Officer , Diagnostic Solutions Segment , Engineering Segment , Full Year , Executive Chairman , North America , European Time , Financial Information , Investor Relations , States Toll Free , Private Securities Litigation Reform Act , Annual Report , Exchange Commission , Marketing Expenses , Administrative Expenses , Constant Currency Revenue , Adjusted Operating Profit , Adjusted Operating Profit Margin , Adjusted Net Profit , Adjusted Diluted , Capital Employed , Net Cash , Free Cash Flow , Constant Currency , Operating Profit , Income Taxes , Italian Tax , Intangible Assets , Guidance Reported , Net Profit , New Plants , Stevanato , Group , Reports , Second , Quarter , 022 , Financial , Results ,